Lumida
/ALT
⌘K
Altimmune Inc

Altimmune Inc

ALT
$2.87USD↑+0.70%+0.02 today

MARKET CAP

558.1M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$3 – $3

52W RANGE

$3
$6

AI Summary

Stalk
TrimMedium

In the Stage 4 decline, ALT remains in a lower-high/lower-low sequence below all major EMAs. Price action is sideways and indecisive around the 9/21 EMA band with RSI neutral. Medium-term structure is bearish while the long-term trend stays up. Execution calls for trimming into rallies up to the EMA resistance zone.

  • ↑Secured $535M cash runway to support Phase 3 MASH trials through 2029
  • ↑59.1% of subjects achieved MASH resolution at 24 weeks in Pembedutide trial
  • ↓Earnings yield remains negative and profitability metrics are weak
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Altimmune, Inc. (NASDAQ: ALT) is a biopharmaceutical company focused on developing innovative therapies for liver diseases, specifically targeting Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), and Alcoholic Liver Disease (ALD). The company’s lead candidate, Pembidutide, utilizes a dual-agonist mechanism to optimize patient outcomes by addressing both metabolic and liver health, thereby positioning Altimmune as a promising player in the rapidly growing market for liver therapeutics.

Bull says

  • ↑Secured $535M cash runway to support Phase 3 MASH trials through 2029
  • ↑59.1% of subjects achieved MASH resolution at 24 weeks in Pembedutide trial
  • ↑Q3 2026 AUD trial top-line data could drive new catalysts
  • ↑Dual GLP-1/glucagon mechanism addresses both liver and metabolic disease
  • ↑Favorable liquidity, optimistic analyst revisions and strong quantitative score
  • ↑Potential breakthrough therapy designation could accelerate regulatory path

Bear says

  • ↓Earnings yield remains negative and profitability metrics are weak
  • ↓Intensifying MASH competition heightens differentiation and pricing risks
  • ↓Phase 3 PERFORMER trial faces execution as enrolment and timelines remain tight
  • ↓Adverse events or discontinuations could hinder physician and patient uptake
  • ↓Cash runway exposed to escalating R&D costs and any trial delays
  • ↓Small company size and high leverage sensitivity pose funding risks

Investment themes with ALT

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-13-2026bullish

Transcript signals

Bull points

  • The potential target product profile for Pembedutide and MASH includes strong early metabolic benefits, significant improvements in inflammation and fibrosis, and quality weight loss that also helps preserve lean muscle mass, combined with a patient-friendly, simple titration that leads to a low rate of discontinuation due to GI side effects.
  • Results showed that both the 1.2 and 1.8 milligram doses of Pembe were efficacious, showing early evidence of MASH resolution and NIT-based antifibrotic effects while being well tolerated.
  • We continue to believe very strongly in the potential of Pembidutide to offer meaningful benefits to patients with MASH and that its potential unique attributes position it well to stand out in a commercial setting.

Bear points

  • The net loss for the first quarter 26 is $22.6 million or 18 cents a share compared to a net loss of $19.6 million or 26 cents per share in the first quarter of 2025.
  • The net loss for the first quarter 26 is $22.6 million or 18 cents a share compared to a net loss of $19.6 million or 26 cents per share in the first quarter of 2025.
Read full transcript analysis ›